Search

The role of contrast medium osmolality in postmyelographic arachnoiditis was studied. Monkeys were injected intrathecally with isotonic saline (290 mOs/kg), hypertonic saline (1,449 mOs/kg), metrizamide (456 or 300 mOs/kg), or methylglucamine iocarnate (1,049 mOs/kg). After 12 weeks the animals were examined for evidence of arachnoiditis, with myelography just prior to sacrifice and microscopic examination of the excised dural sac and its contents. Intrathecal injections of methyglucamine iocarmate or metrizamide caused arachnoiditis while saline did not. Only one animal given 170 mg l/ml (300 mOs/kg) exhibited a more severe reaction than the controls. An increase in the cerebrospinal fluid osmolality alone does not cause arachnoiditis.

The effectiveness of prophylactic intrathecal methylprednisone (MP) in preventing arachnoiditis from iocarmate myelography was studied. Monkeys were injected intrathecally with locarmate, MP, or a combination of the two. Twelve weeks later the severity of arachnoiditis was determined in each animal. There was no significant prophylactic effect of intrathecal MP on arachnoiditis from locarmate. Some arachnoiditis was found in control animals treated with MP alone.

Myelography with meglumine iocarmate, a dilute meglumine iocarmate solution, or gas was performed in macaque monkeys. Twelve weeks later the animals were examined myelographically and histologically for evidence of arachnoiditis. Arachnoiditis in the animals treated with dilute meglumine iocarmate and gas was significantly less than in those treated with meglumine iocarmate.

After myelography with either metrizamide (300mg l/ml) or meglumine iocarmate (280 mg l/ml), mild to severe arachnoid fibrosis was demonstrated radiographically and histologically in primates. Intrathecal injections of metrizamide (170 mg l/ml) or autologous cerebrospinal fluid produced less arachnoiditis. The risk of arachnoiditis is probably minimized by the use of reduced volumes and concentrations of water-soluble media. Controlled studies of arachnoiditis following myelography are probably more reliable in the primate model than in other experimental animals.

Myelography was performed on 80 monkeys to study postmyelographic arachnoiditis. Metrizamide myelography caused arachnoiditis when high concentrations were used, but not with the usual clinical concentrations. Arachnoiditis resulted after myelography with meglumine iocarmate; however, the risk of arachnoiditis was reduced by diluting the contrast medium. Prophylactic intrathecal methylprednisolone was not effective in preventing arachnoiditis. Blood in the cerebrospinal fluid did not affect the degree of arachnoiditis.

Myelography in monkeys was performed with either meglumine iocarmate or metrizamide. The severity of resultant arachnoiditis in each animal 12 weeks later was evaluated by repeat myelography and by histologic study of the arachnoid. Three of the four animals examined with meglumine iocarmate had severe arachnoiditis; none of the four animals examined with metrizamide had as severe changes. The difference between the two groups was statistically significant (P less than .05).

Monkeys were injected intrathecally with blood, metrizamide (Amipaque) or a mixture of blood and metrizamide. Twelve weeks later the animals were examined for evidence of arachnoiditis. Either blood or metrizamide alone in sufficient amounts resulted in arachnoiditis. The addition of blood to metrizamide did not alter the severity or risk of arachnoiditis from experimental myelography with metrizamide.